Tags Archive Navigation
icon
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile
-
Media ReleaseNovartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
-
Media ReleaseNovartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma
-
Media ReleaseNovartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
-
Media ReleaseNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Media ReleaseNovartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
-
Media ReleaseFDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran